Qiagen QIA.DE
What does Qiagen do?
Qiagen is a company specializing in molecular diagnostics and life science research, headquartered in the Netherlands. It provides solutions that turn biological samples into usable molecular insights. These include consumables for the stabilization and purification of nucleic acids, instruments for sample preparation and quality control, as well as test systems and analysis software.
Qiagen generates most of its revenue from recurring consumables used on installed instruments. Its customers are hospitals, laboratories, pharmaceutical and biotechnology companies, and academic research institutions. Important fields of application include tests of immune response, for example to tuberculosis, monitoring of viral infections after transplants, oncology, and tests in reproductive and sexual health. Competitively, Qiagen is regarded as an established provider of sample preparation. Its competitors range from large diagnostics and life science groups to specialized providers. Differentiation comes from the installed instrument base, market approvals and partnerships with pharmaceutical companies.
Score profile
Rank vs. Diagnostics & Research (25 companies). 10 = top of the group, 5 = middle. Calculated from the metrics below, without AI.
Metrics compared with the industry
On profitability and quality, Qiagen ranks above average in the group Diagnostics & Research (7.4/10). On growth, the company ranks in the bottom fifth in the group Diagnostics & Research (1.0/10). On valuation (higher = cheaper), the stock ranks above average in the group Diagnostics & Research (6.8/10). On financial strength, Qiagen ranks above average in the group Diagnostics & Research (7.1/10).
| Metric | Stock | Group median | Ranking |
|---|---|---|---|
| Forward P/E | 19.6x | 26.0x | better than 80 % |
| Trailing P/E | 28.5x | 36.2x | better than 73 % |
| PEG ratio | 1.3x | 1.7x | better than 63 % |
| EV/EBITDA | 14.8x | 21.2x | better than 80 % |
| Price/sales | 4.9x | 4.9x | better than 50 % |
| Price/book | 3.0x | 4.9x | better than 69 % |
| Revenue growth | 2.9% | 8.5% | better than 10 % |
| Earnings growth | -19.2% | 16.3% | better than 10 % |
| Gross margin | 67.0% | 54.6% | better than 86 % |
| Operating margin | 26.7% | 16.0% | better than 86 % |
| Net margin | 18.2% | 9.5% | better than 74 % |
| Return on equity | 10.8% | 10.8% | better than 50 % |
| Debt/equity | 47.4% | 54.1% | better than 65 % |
| Current ratio | 2.6x | 1.9x | better than 70 % |
| Free cash flow yield | 3.6% | 2.7% | better than 78 % |
| Dividend yield | 0.7% | 0.8% | – |
| Payout ratio | 19.0% | 24.4% | – |
| Beta | 0.56 | 1.17 | – |
Valuation: what is Qiagen worth?
Two valuation approaches – a discounted cash flow model and a valuation at the industry’s median multiples – give Qiagen a model range of 28.40 EUR to 66.48 EUR per share.
5 analysts, average rating “Hold”, average price target 43.10 EUR (−4.9%).
The full DCF matrix, the reverse DCF (what growth the price implies) and scenarios are part of the Pro analysis.
What the business depends on
- Recurring consumables on an installed instrument base provide predictable revenue and tie customers to the platforms over the long term.
- Demand for molecular diagnostics, for example in oncology and infectious diseases, rises with the spread of personalized medicine.
- Partnerships with pharmaceutical companies for companion diagnostics open up additional applications and strengthen the position in oncology.
Risks
- Regulatory approvals and reimbursement decisions can delay market launches and affect the profitability of new tests.
- Competitors with greater resources and competing technologies can gain market share and create price pressure.
- Fluctuating research budgets and investment by pharmaceutical and academic customers, as well as currency effects, weigh on business performance.
What to look for with Qiagen
The share of recurring consumables revenue in total revenue is informative because it reflects the stability and predictability of the platform-based business model.